Compare SHG & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHG | ONC |
|---|---|---|
| Founded | 1982 | 2010 |
| Country | South Korea | Switzerland |
| Employees | N/A | 12000 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9B | 31.4B |
| IPO Year | 2003 | N/A |
| Metric | SHG | ONC |
|---|---|---|
| Price | $67.39 | $309.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $374.75 |
| AVG Volume (30 Days) | ★ 263.8K | 187.3K |
| Earning Date | 04-24-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.86 | $747.23 |
| Revenue Next Year | $3.66 | $15.78 |
| P/E Ratio | ★ $9.79 | $614.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.86 | $227.40 |
| 52 Week High | $73.40 | $385.22 |
| Indicator | SHG | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 65.96 | 54.97 |
| Support Level | $58.10 | $307.93 |
| Resistance Level | $73.40 | $320.35 |
| Average True Range (ATR) | 1.41 | 7.68 |
| MACD | 0.76 | 4.77 |
| Stochastic Oscillator | 96.10 | 82.89 |
Shinhan Financial Group Co Ltd is a Korean banking group. Along with its subsidiaries the company provides, comprehensive financial services which consist of commercial banking services, credit card services, securities services, insurance, credit services, and asset management services, including securities investment trust management, investment advisory, call transaction, domestic and foreign private equity fund business, and other services. The majority of the revenue is generated from its Banking business which includes retail, corporate, international, and other banking services the company offers.
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.